Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs

The J.P. Morgan Healthcare Conference may be over, but that doesn’t mean the dealmaking is. Often, deals that took shape at the meeting materialize later in the year, and some recent buzz puts Pfizer and Biogen at the center of potential takeovers.